News

Alette Verbeek and Sharon Curran are being nominated by the main shareholders, Wagner Family Holding ApS (approx. 58% ownership) and Chr. Augustinus Fabrikker Aktieselskab (approx. 35% ownership). All shareholders have been invited to an extraordinary general meeting on 4th October, 2024.

The Abacus Medicine Group celebrates its 20th anniversary. We have experienced a fantastic development through 20 years of uninterrupted growth. With your help, we have grown into one of the 100 largest companies in Denmark, and have been the only Danish company to receive 12 gazelles from Børsen.

Under the terms of the agreement, Mirum Pharmaceuticals has appointed Abacus Medicine Pharma Services to exclusively promote, market, sell, distribute, and commercialize LIVMARLI in the territory of Denmark, Finland, Iceland, Norway, and Sweden.

In 2023, sustainability became an enabler of our Access26 strategy – an important step towards ensuring a deeper integration of sustainability in all our processes and operations. Throughout the year, we also prepared for the upcoming Corporate Sustainability Reporting Directive, under which we need to report in 2026.

The Abacus Medicine Group exceeded the guidance ranges for both revenue and profitability in 2023. A combination of high demand in core sales markets and solid commercial execution drove organic revenue growth of 18% to EUR 1,210 million and EBITDA growth of 82% to EUR 47.5 million.

Jens Harsaae is being nominated as new Chairman of Abacus Medicine A/S by the main shareholders.